<DOC>
	<DOCNO>NCT00360971</DOCNO>
	<brief_summary>RATIONALE : Growth factor , palifermin , may lessen severity mucositis , mouth sore , patient receive radiation therapy chemotherapy head neck cancer . It yet know whether palifermin effective placebo lessen mucositis patient receive radiation therapy chemotherapy head neck cancer . PURPOSE : This randomized phase III trial study palifermin see well work compare placebo lessen oral mucositis patient undergo radiation therapy chemotherapy locally advanced head neck cancer .</brief_summary>
	<brief_title>Palifermin Lessening Oral Mucositis Patients Undergoing Radiation Therapy Chemotherapy Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy palifermin v placebo , term burden acute mucositis ( defined 105 day [ 15 week ] less start treatment ) , patient squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx undergoing concurrent radiotherapy chemotherapy . Secondary - Compare incidence time onset Grades 3 4 oral mucositis patient treat regimen . - Compare overall progression-free survival time second primary patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord disease stage ( III vs IVA IVB ) , tumor site ( oral cavity oropharynx v hypopharynx larynx ) , radiotherapy technique use study ( intensity-modulated radiotherapy [ IMRT ] v 3-dimensional conformal radiotherapy [ 3D-CRT ] ) . Patients randomize 1 2 treatment arm . Mucositis , pain , symptom burden assess baseline , radiotherapy , post radiotherapy . Xerostomia assess baseline , radiotherapy , several time completion study therapy . After completion study therapy , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 298 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx , meet follow criterion : At least 2 mucosal sit oral cavity/oropharynx mucosa irradiate assessable visual transoral inspection Tumors larynx hypolarynx allow anticipate 2 index site oral cavity/oropharynx mucosa irradiate Selected stage III ( exclude T1 , N1 , M0 ) , IVA IVB disease No distant metastases stage IVC disease ( T , N , M1 ) No prior squamous cell cancer head neck PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute neutrophil count ≥ 1,800/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Bilirubin &lt; 1.5 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal Creatinine &lt; 1.5 mg/dL Creatinine clearance ≥ 50 mL/min Able eat least soft solid require feed tube nutrition hydration Calcium normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free ≥ 3 year No severe , active comorbidity , include follow : Symptomatic and/or uncontrolled cardiac disease ( i.e. , New York Heart Association class IIIIV cardiac disease ) Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require intravenous antibiotic Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization Hepatic insufficiency result clinical jaundice and/or coagulation defect Seropositive hepatitis B virus hepatitis C virus Seropositive HIV confirm AIDS History pancreatitis Collagen vascular disease , scleroderma No prior allergic reaction know sensitivity agent administer study dosing , include E. coliderived product , follow : Somatropin ( somatren ) Filgrastim ( GCSF ) Insulin Interferon alfa2a Neumega® Oprelvekin ( interleukin11 ) Interferon alfa2b Pegfilgrastim Interferon beta1b PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy cancer Prior chemotherapy different cancer allow No prior radiotherapy region would result overlap radiation therapy field No prior radical modify neck dissection No prior initial surgical treatment , exclude diagnostic biopsy primary site nodal sample neck disease No prior palifermin keratinocyte growth factor ( i.e. , velafermin repifermin ) Concurrent topical anesthetic allow No concurrent administration follow radiotherapy : 'Magic ' mouthwash , 'Miracle ' mouthwash , mouthwash solution contain chlorhexidine , Gelclair® , hydrogen peroxide , diphenhydramine Pilocarpine hydrochloride Cevimeline hydrochloride Amifostine Benzydamine hydrochloride Interleukin11 Sargramostim ( GMCSF ) Epoetin alfa Sucralfate suspension form Tablets allow Steroid rinse Povidoneiodine rinse Glutamine prophylactic agent mucositis Other investigational agent Other biologic response modifier , exception hematopoietic growth factor management anemia myelosuppression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>mucositis</keyword>
	<keyword>pain</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>